Invited review: Drug development for tauopathies.
Basel, Switzerland. In Neuropathol Appl Neurobiol, Feb 2015
Many different approaches to treating tauopathies are currently being explored, with a few compounds already in clinical development (including small molecules such as anti-aggregation compound LMTX and active vaccines AADvac1 and ACI-35).
The HRASLS (PLA/AT) subfamily of enzymes.
Waterloo, Canada. In J Biomed Sci, 2014
The H-RAS-like suppressor (HRASLS) subfamily consists of five enzymes (1-5) in humans and three (1, 3, and 5) in mice and rats that share sequence homology with lecithin:retinol acyltransferase (LRAT).